Market Whales and Their Recent Bets on AMGN Options
This Is What Whales Are Betting On Gilead Sciences
Actinium Wins FDA Nod to Conduct Clinical Trial for Radiotherapy
Biomarin Pharmaceutical Analyst Ratings
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
Neurocrine Biosciences Analyst Ratings
BioMarin Gets Expanded FDA Approval for CLN2 Therapy Brineura
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Leerink Upgrades Ionis to Outperform, Cites Angelman Drug
Albemarle Is Out of Wells Fargo's Signature Picks
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain
Amgen, Garmin Among Relative Market Leaders Poised to Outperform in Coming Months: BTIG
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Ionis Pharmaceuticals Analyst Ratings
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst